(Source: MyoKardia Inc) MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied Company Plans to Initiate Phase 2 PIONEER-HCM Study in Second Half of 2016 MyoKardia R&D Day Planned for Fall; Abstract Submitted for Presentation at The American Heart Association's Scientific Sessions 2016 Company to Host Conference Call and Webcast Today at 2:00 PM PT (5:00 PM ET) SOUTH SAN FRANCISCO, Calif., July 11, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular...
↧
